Details of the Drug

General Information of Drug (ID: DMWJXFO)

Drug Name
Mezagitamab
Synonyms TAK-079
Indication
Disease Entry ICD 11 Status REF
Myasthenia gravis 8C6Y Phase 2 [1]
Primary immune thrombocytopenia 3B64.10 Phase 2 [2]
IgA nephropathy MF8Y Phase 1 [3]
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D54QKH
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclic ADP-ribose hydrolase 1 (CD38) TTPURFN CD38_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Myasthenia gravis
ICD Disease Classification 8C6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cyclic ADP-ribose hydrolase 1 (CD38) DTT CD38 8.33E-02 0.22 0.69
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04159805) A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Generalized Myasthenia Gravis. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04278924) A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05174221) A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background Therapy. U.S.National Institutes of Health.
4 Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti-CD38 cytolytic antibody TAK-079 in healthy subjects. Br J Clin Pharmacol. 2020 Jul;86(7):1314-1325.